Can meta-analysis suggest carboplatin/paclitaxel as a reference arm in randomized trials of first-line chemotherapy for advanced non-small cell lung cancer?

被引：0
|
作者：
Yamanaka, T.
Yamamoto, N.
Seto, T.
Takahashi, T.
Murakami, H.
Tsuya, A.
Naito, T.
Kaira, K.
Nakamura, Y.
Ichinose, Y.
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19039
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
    Mogollon-Duffo, F.
    Sultan, A.
    Swarup, S.
    Jahan, N.
    Tun, A. M.
    Htut, T. Win
    Naing, T. W.
    Naing, P. T.
    Myat, Y. Mon
    Hardwicke, F.
    Rehman, S.
    Tijani, L.
    D'Cunha, N.
    Thein, K. Z.
    ANNALS OF ONCOLOGY, 2019, 30 : 621 - 621
  • [2] Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
    Tun, Aung Myint
    Thein, Kyaw Zin
    LinThein, Wai
    Guevara, Elizabeth
    FUTURE SCIENCE OA, 2019, 5 (09):
  • [3] Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
    Pujol, Jean-Louis
    Pirker, Robert
    Lynch, Thomas J.
    Butts, Charles A.
    Rosell, Rafael
    Shepherd, Frances A.
    Vansteenkiste, Johan
    O'Byrne, Kenneth J.
    de Blas, Barbara
    Heighway, Jim
    von Heydebreck, Anja
    Thatcher, Nick
    LUNG CANCER, 2014, 83 (02) : 211 - 218
  • [4] A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer
    Jiang, Haiping
    Zhang, Xiaochen
    Chen, Jing
    Zhang, Ling
    Xiong, Jianping
    Zhong, Lin
    Yu, Feng
    Qian, Jiong
    Yu, Lanfang
    Wang, Xiaoting
    Shi, Genming
    Deng, Jing
    Xu, Nong
    JOURNAL OF THORACIC DISEASE, 2014, 6 (02) : 79 - 85
  • [5] Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy
    Park, Hyung Soon
    Lim, Sun Min
    Shin, Ho Jung
    Cho, Arthur
    Shin, Jae-Gook
    Lee, Min Goo
    Kim, Hye Ryun
    Kim, Joo Hang
    Cho, Byoung Chul
    PHARMACOGENETICS AND GENOMICS, 2016, 26 (03): : 116 - 125
  • [6] Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
    da Silveira Nogueira Lima, Joao Paulo
    dos Santos, Lucas Vieira
    Sasse, Emma Chen
    Sasse, Andre Deeke
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) : 601 - 607
  • [7] Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    LUNG CANCER, 2011, 74 (03) : 469 - 473
  • [8] Cardiotoxic effects of gemcitabin/cisplatin vs paclitaxel/carboplatin first-line chemotherapy in patients with advanced non-small cell lung cancer
    Bursac, D. S.
    Sarcev, T.
    Velikic, D. Sazdanic
    Tepavac, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Li, Ming
    Zhang, Qian
    Fu, Peifang
    Li, Ping
    Peng, Aimei
    Zhang, Guoliang
    Song, Xiaolian
    Tan, Min
    Li, Xuan
    Liu, Yang
    Wu, Yueping
    Fan, Suyun
    Wang, Changhui
    PLOS ONE, 2012, 7 (05):
  • [10] Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
    Thein, Wai Lin
    Tun, Aung
    Thein, Kyaw Zin
    Guevara, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345